• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CWWeekly November 12th Issue

CWWeekly November 12th Issue

November 16, 2007
CenterWatch Staff

Top News

 

Ergomed Opens Office in Dubai

Frankfurt, Germany-based contract research organization (CRO) Ergomed Group has opened a new regional headquarters in Dubai City's new life sciences research park, DuBiotech. The company plans to use the office as a hub for its operations in the Middle East and India. The company’s main headquarters is located in the Frankfurt Biotechnology Innovation Center, which has collaborated with DuBiotech since 2005. The center brought the CRO and DuBiotech together to discuss the opportunities in Dubai and an agreement was made just a few months later. The 20 million square-foot space, or nearly one square-mile, was set aside by the Dubai government for the research park to attract international research and development companies to do business in the Dubai emirate, a state within the United Arab Emirates.

Averion Buys Hesperion

Southborough, Mass.-based contract research organization (CRO) Averion International acquired Swiss-based CRO Hesperion AG from its French parent company Cerep SA. Averion will pay $36.2 million forvthe company. To finance the acquisition, Averion issued three-year senior secure notes on the company’s current debt. The debt financing raised $24 million towards the purchase. Phillip Lavin, Ph.D., resigned as chief executive officer of Averion on Oct. 31, and was immediately appointed as executive chairman of the company. He was replaced by Hesperion’s chief executive officer Dr. Markus Weissbach, who was appointed head of Hesperion in September 2006.

Other breaking news...

  • ICON reports strong third quarter revenues...
  • AAIPharma opens office in Hungary...

Company Profile: An interview with Kristine Kuryla, operations manager, University of Rochester Medical Center Clinical Trial Central Laboratory

To read the full articles for this issue or for more information on these and other breaking stories, please
click here
for subscription information.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing